Oral Rapamycin After Coronary Bare-Metal Stent Implantation to Prevent Restenosis
The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study
Alfredo E. Rodriguez, MD, PhD, FACC*,*,
Juan F. Granada, MD
,
Máximo Rodriguez-Alemparte, MD*,
Cesar F. Vigo, MD*,
Juan Delgado, MD
,1,
Carlos Fernandez-Pereira, MD*,
Antonio Pocovi, MD*,
Alfredo M. Rodriguez-Granillo, BS*,
Daryl Schulz, RTN
,
Albert E. Raizner, MD, FACC
,
Igor Palacios, MD, FACC
,
William ONeill, MD, FACC
,
Grzegorz L. Kaluza, MD, PhD
,
Gregg Stone, MD, PhD, FACC|| for the ORAR II Investigators
* Otamendi Hospital, Buenos Aires, Argentina
The Methodist Hospital Research Institute, Houston, Texas
Massachusetts General Hospital, Boston, Massachusetts
William Beaumont Hospital, Royal Oak, Michigan
|| Columbia University, New York, New York Dr.

View larger version (13K):
[in a new window]
|
Figure 1 Kaplan-Meier curves showing event-free survival from target lesion revascularization (A), target vessel revascularization (B), and major adverse cardiovascular events (C) for the global follow-up. The p values were calculated using the log-rank test.
|
|
Copyright © 2006 by the American College of Cardiology Foundation.